Our Management Team

Srinivasa Nagalla, M.D. President and Chief Executive Officer

Dr. Nagalla is the principal founder and chief executive officer of DiabetOmics. He was previously founder and CEO of ProteoGenix, Inc., a successful innovator in maternal-fetal health diagnostics, which was acquired by Hologic, Inc. (HOLX) in 2010. Before founding ProteoGenix, Dr. Nagalla was Associate Professor of pediatrics at Oregon Health & Science University. He is the lead inventor on several key patents on biomarkers for clinical diagnostics, and has previously served on National Institutes of Health-sponsored national consortiums of biotechnology, genomics, and proteomics. Dr. Nagalla has 20+ years of broad multi-disciplinary experience in clinical medicine, biotechnology, and commercialization. Dr. Nagalla received his M.D. from the All-India Institute of Medical Sciences, New Delhi, and post-doctoral training at Harvard University and Oregon Health & Science University.

David Gunderson Chief Financial Officer and Executive Vice President

David Gunderson joined Diabetomics in 2010. Prior to coming to DiabetOmics, Mr. Gunderson ran a fund for the State of Oregon and was a Principal in Erickson Capital from 2000-2009, a venture capital firm. From 1985 to 1999, he served at Sequent Computer Systems as Controller and Vice President of Indirect Channel Sales (including the Federal Government), Vice President of Sales for Asia Pacific and then, as Vice President of Business Development, negotiated its sale to IBM. Mr. Gunderson started his career as a CPA with Arthur Andersen & Co, from 1978 to 1985. He has served on several for-profit and non-profit boards and has chaired many major capital campaigns. David received his Bachelor’s degree in Accounting from the University of Oregon. Mr. Gunderson has been a Type 1 diabetic for the last 47 years.

Paturi V. Rao, M.D., Ph.D., F.R.C.P.

Dr. Rao is co-founder and chief medical officer since 2008, and is responsible for DiabetOmics operations in India and Asia. Dr. Rao is Professor and Chief of Endocrinology at Nizam’s Institute of Medical Sciences University in Hyderabad, India. Dr. Rao founded and served as Secretary of Research Society for the Study of Diabetes in India (RSSDI) from 1997-2003. RSSDI is the largest diabetes care provider’s organization in Asia, with more than 7000 member diabetologists. Dr. Rao has served as principal investigator on several key international clinical studies in diabetes, including ORIGIN, DREAM, and several phase-II and phase-III clinical trials for Novo Nordisk, Eli Lilly, Aventis, Merck Scharpe & Dohme, Novartis, and Johnson & Johnson. Dr. Rao serves on the advisory committees of the Indian Council of Medical Research, Department of Science & Technology, and several pharmaceutical companies.

Charles Roberts, Ph.D. Vice President and Chief Science Officer

Dr. Roberts is co-founder and chief science officer since 2008. Dr. Roberts is a molecular endocrinologist with over 25 years of experience in diabetes research, is an internationally recognized expert on insulin action, and has authored over 250 scientific papers and review articles. Dr. Roberts is also a co-inventor on various patents on therapeutics and biomarkers for clinical diagnostics, and serves on numerous review panels for the National Institutes of Health and the editorial boards of several major biomedical research journals. From 1984-1994, he was a Senior Investigator in the Diabetes Branch of the National Institutes of Health in Bethesda, MD, and subsequently Professor and Associate Chair for Research in the Department of Pediatrics and Professor of Medicine at Oregon Health & Science University.

Steven Kazmierczak, Ph.D., DABCC. CLIA Laboratory Director

Dr. Kazmierczak joined Diabetomics in 2010 and serves as the director of CLIA laboratory operations. He is Director of Chemistry and Toxicology at Oregon Health & Science University. He is board-certified in chemical pathology, and has interests in the development, evaluation, and clinical application of diagnostic laboratory test systems. He serves as Director of the Scientific Advisory Board for ABAXIS Corp., Gamma Therapeutics, and Albumetix. Dr. Kazmierczak is also on the editorial board of several journals specializing in laboratory medicine, is Associate Editor of Clinical Chemistry and Laboratory Medicine, and serves on numerous national committees for the AACC, ASCP, and CAP.